A study by the University of Surrey and Royal Surrey County Hospital in the UK has demonstrated that a strain of the common cold virus could help the immune system to kill non-muscle invasive bladder cancer (NMIBC).

Tumours in the bladder often require intervention to trigger an immune response, as they use various mechanisms to avoid detection by immune cells. The researchers suspect that the common cold virus was able to support the immune system by inflaming the tumour.

In one study participant, all signs of the cancer were found to have disappeared.

NMIBC is the tenth most common cancer in the UK. It is currently treated using transurethral resection, which is associated with a high recurrence rate. Another common approach involving immunotherapy with the bacille calmette-guerin bacterium is known to have serious side effects or no effect in certain patients.

During the latest study, 15 NMIBC patients were given the cancer-killing coxsackievirus (CVA21) virus through a catheter one week before their tumour-removal surgery.

Post-surgical tissue sample analysis showed that the virus selectively targeted cancerous cells without affecting healthy tissues. The virus replicated itself in the cancer cells, leading to their death.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the majority of subjects, the virus led to cancer cell death, while one patient had no traces of the disease after treatment. The team detected no side effects in any patient.

The University of Surrey medical oncology professor Hardev Pandha said: “Reduction of tumour burden and increased cancer cell death was observed in all patients and removed all trace of the disease in one patient following just one week of treatment, showing its potential effectiveness.”